Leipzig, Germany – ADME-Tox product developer Nimbus Biotechnologie has changed its name to Sovicell, effective immediately. The company says the change reflects its move to become a full range, international supplier of ADME-Tox products and services for pre-clinical research.
Founded in 1994, the company produces bead-based in vitro testing procedures for reliably measuring a drug candidate’s membrane permeability and protein binding. The testing can enable early and accurate prediction of the efficacy and safety of drug candidates and prevent costly failures in clinical trials.
Have your say: